222 related articles for article (PubMed ID: 38030698)
1. Functional analysis of recurrent CDC20 promoter variants in human melanoma.
Godoy PM; Oyedeji A; Mudd JL; Morikis VA; Zarov AP; Longmore GD; Fields RC; Kaufman CK
Commun Biol; 2023 Nov; 6(1):1216. PubMed ID: 38030698
[TBL] [Abstract][Full Text] [Related]
2. Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome.
Poulos RC; Thoms JA; Shah A; Beck D; Pimanda JE; Wong JW
Mol Cancer Res; 2015 Aug; 13(8):1218-26. PubMed ID: 26082173
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer noncoding genomic analysis identifies functional
He Z; Wu T; Wang S; Zhang J; Sun X; Tao Z; Zhao X; Li H; Wu K; Liu XS
iScience; 2021 Apr; 24(4):102285. PubMed ID: 33851100
[TBL] [Abstract][Full Text] [Related]
4. Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes.
Parker SC; Gartner J; Cardenas-Navia I; Wei X; Ozel Abaan H; Ajay SS; Hansen NF; Song L; Bhanot UK; Killian JK; Gindin Y; Walker RL; Meltzer PS; Mullikin JC; Furey TS; Crawford GE; Rosenberg SA; Samuels Y; Margulies EH
PLoS Genet; 2012; 8(8):e1002871. PubMed ID: 22912592
[TBL] [Abstract][Full Text] [Related]
5.
Zhang T; Xu M; Makowski MM; Lee C; Kovacs M; Fang J; Willems E; Trent JM; Hayward NK; Vermeulen M; Brown KM
Cancer Res; 2017 Apr; 77(7):1649-1661. PubMed ID: 28108517
[No Abstract] [Full Text] [Related]
6. Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers.
Elliott K; Boström M; Filges S; Lindberg M; Van den Eynden J; Ståhlberg A; Clausen AR; Larsson E
PLoS Genet; 2018 Dec; 14(12):e1007849. PubMed ID: 30586386
[TBL] [Abstract][Full Text] [Related]
7. Cancer regulatory variation.
Hennessey RC; Brown KM
Curr Opin Genet Dev; 2021 Feb; 66():41-49. PubMed ID: 33422949
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional and post-transcriptional regulation of Cdc20 during the spindle assembly checkpoint in S. cerevisiae.
Wang R; Burton JL; Solomon MJ
Cell Signal; 2017 May; 33():41-48. PubMed ID: 28189585
[TBL] [Abstract][Full Text] [Related]
9. Novel Mutations in CDC20 Are Associated with Female Infertility Due to Oocyte Maturation Abnormality and Early Embryonic Arrest.
Huang L; Wang F; Kong S; Wang Y; Song G; Lu F; Ji J; Luo L; Tong X
Reprod Sci; 2021 Jul; 28(7):1930-1938. PubMed ID: 33683667
[TBL] [Abstract][Full Text] [Related]
10. Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.
Colebatch AJ; Di Stefano L; Wong SQ; Hannan RD; Waring PM; Dobrovic A; McArthur GA; Papenfuss AT
Oncotarget; 2016 Oct; 7(41):66569-66585. PubMed ID: 27611953
[TBL] [Abstract][Full Text] [Related]
11. TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma.
Chun-On P; Hinchie AM; Beale HC; Gil Silva AA; Rush E; Sander C; Connelly CJ; Seynnaeve BKN; Kirkwood JM; Vaske OM; Greider CW; Alder JK
Science; 2022 Nov; 378(6620):664-668. PubMed ID: 36356143
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
13. Detecting recurrent passenger mutations in melanoma by targeted UV damage sequencing.
Selvam K; Sivapragasam S; Poon GMK; Wyrick JJ
Nat Commun; 2023 May; 14(1):2702. PubMed ID: 37169747
[TBL] [Abstract][Full Text] [Related]
14. CDC20 contributes to the development of human cutaneous squamous cell carcinoma through the Wnt/β‑catenin signaling pathway.
Chu Z; Zhang X; Li Q; Hu G; Lian CG; Geng S
Int J Oncol; 2019 May; 54(5):1534-1544. PubMed ID: 30816486
[TBL] [Abstract][Full Text] [Related]
15. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
16. Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.
Feng Y; Shi J; Goldstein AM; Tucker MA; Nelson MA
Int J Cancer; 2002 Jun; 99(6):834-8. PubMed ID: 12115485
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional control analyses of the Xiphophorus melanoma oncogene.
Regneri J; Volff JN; Schartl M
Comp Biochem Physiol C Toxicol Pharmacol; 2015 Dec; 178():116-127. PubMed ID: 26348392
[TBL] [Abstract][Full Text] [Related]
19. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature.
Fredriksson NJ; Elliott K; Filges S; Van den Eynden J; Ståhlberg A; Larsson E
PLoS Genet; 2017 May; 13(5):e1006773. PubMed ID: 28489852
[TBL] [Abstract][Full Text] [Related]
20.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
